For a while now, there has been a shortage of diabetes medication, and some of it was due in part to the weight loss fad surrounding Ozempic. Celebrities and influencers have touted the drug as a miracle weight loss drug. But, at $1,000 a prescription, they can do that. The rest of America? Not so much.

However, another diabetes drug is coming onto the market that may help patients lose weight even faster. Eli Lilly’s Mounjaro has been tested for weight loss and some patients around 230 pounds saw a 50-pound loss after 17 months.

The Wall Street Journal is calling it the “King Kong” of weight loss drugs, and it stands to make Eli Lilly a fortune.

No anti-obesity drug has ever safely made such a difference. In the coming months, it is widely expected to get the go-ahead from U.S. health regulators to be prescribed for losing weight and keeping it off, and some patients are already using it unapproved for that purpose.

The advance of Mounjaro, which is already on the market to treat Type 2 diabetes, has excited doctors and patients who have been waiting decades for effective treatments, while helping turn its maker, Eli Lilly & Co., into themost valuable standalone pharmaceutical company in the U.S. with a market value of more than $300 billion.

It’s a product of Lilly’s recent, sometimes painful overhaul of how it develops drugs. After several costly drug failures, Lilly abandoned some of its long-held practices, including waiting for multiple committees to weigh in before advancing a drug. The company had also been prioritizing its existing successful drug franchises at all costs, sometimes at the expense of promising new treatments.

However, this is not about the excellent advances in weight loss medication. This is about what we can expect in the world of politics before too much longer.

There have been multiple studies regarding obesity and income, and while the NIH has noted that there seems to be a relationship between obesity and income, the research community seems to be divided over whether obesity causes lower income or lower income causes obesity. How one gets there will ultimately not matter to the Democrats, however. It’s the destination, not the journey.

In this case, the destination is poor obese people, and lo and behold, Big Pharma is discriminating against the poor to keep life-saving weight loss drugs out of their hands. While progressive ideology has progressed to “Be comfortable with your body,” the Democrats will see an opportunity to go after the major pharmaceutical companies for yet another drug they will inevitably be accused of “pricing the poor out of.”

You just know that someone like Alexandria Ocasio-Cortez will proclaim that “Weight loss is a human right!” and push for pharmaceutical companies to lower the price of Ozempic and Mounjaro. Insurance companies will be told to cover weight loss drugs or else. It will be codified into the Affordable Care Act.

This is inevitably what happens when the left sees an opportunity to strike at big corporations. Eli Lilly has run trial after trial, poured a ton of money into research and development, and priced these drugs based on all that. Sure, generating a profit is going to happen – in a capitalist society, profit is the only way to advance – but at the end of the day, you aren’t paying $1,000 for a diabetes drug if you have diabetes. You’re only paying $1,000 for a diabetes drug if you plan to take it for weight loss.

But we are inevitably going to get to the point where Eli Lilly is accused of wanting more people to be fat so they can continue selling other drugs. AOC and Bernie Sanders and Elizabeth Warren will all parade out and call Big Pharma evil, greedy pigs, and eventually, there will be some government regulation to force the price down.

This is not how the system is supposed to work, is it?